Enforcement Policy on Marketing OTC Combination Products (CPG 7132b16)
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
May 1, 1984
April 10, 2019
2c77f827-6c1a-4709-983c-c8314f614c3b
Related Documents
Guidance for the Development of Vaginal Contraceptive Drugs (NDA)
Guidance DocumentMarch 2, 1998Center for Drug Evaluation and Research
Preparation of Investigational New Drug Products (Human and Animal): Guidance for Industry
Guidance DocumentNovember 1, 1992Center for Drug Evaluation and Research
Topical Dermatologic Corticosteroids: in Vivo Bioequivalence
Guidance DocumentJune 2, 1995Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.